Woodford shakes off drug pricing woes; Biden taps Soon-Shiong as he focuses on cancer;

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: ICYMI: AstraZeneca's olaparib looks promising for a targeted set of prostate cancer patients. Story | Follow @JohnCFierce

@DamianFierce: Solid use of the double question mark in the otherwise disappointing Citron $VRX screed. More | Follow @DamianFierce

> Despite headwinds related to drug pricing, influential U.K. investor Woodford Funds remains bullish on U.S. biopharma. More

> Controversial entrepreneur Patrick Soon-Shiong has emerged as an ally to Vice President Joe Biden, who has shifted his attention to the fight against cancer. News

> Despite the recent struggles of biotechs trying to go public, Atlas Venture's Michael Gladstone argues it's still a good time to be investing in early-stage drug development companies. Blog

Medical Device News

@FierceMedDev: 450+ hospitals pay DOJ $250M for overuse of ICDs at the expense of Medicare. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI Friday: Quest Medical launches recall for open heart surgery drug delivery devices. Article | Follow @EmilyWFierce

> Conventus bags $21M in equity to commercialize minimally invasive implants to treat fractures. More

> Researchers develop topical device that measures skin health, blood flow. Story

Pharma News

@FiercePharma: Novartis sees doc-education push, DTC as crucial to amping up Entresto launch. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: ICYMI: Pfizer and GlaxoSmithKline are collaborating on continuous manufacturing. FiercePharmaManufacturing item | Follow @EricPFierce

@CarlyHFierce: Shire locks down rivals to its rare-disease franchise with $5.9B Dyax buy. News | Follow @CarlyHFierce

> It's open season for Mylan's EpiPen as Sanofi, Teva stumble. Item

> FDA finds fault with Pfizer China plant. Story

> JAMA: 'Groundbreaking,' 'miracle' drugs not all they're cracked up to be in news stories. More

Animal Health News

> Investors cheer Abaxis but trounce IDEXX on quarterly diagnostics performance. More

> NexGard demand drives strong Q3 growth for Sanofi's Merial. Item

> Tufts vet borrows techniques from human medicine to repair facial fractures in dogs. Story

> Colorado State University scientists use fertility know-how to revive Yellowstone bison. Report

> VCA beats on earnings but misses the mark on revenue in Q3. Article

Biotech IT News

> Ex-BGI CEO sets up AI-enabled health data mining operation. Report

> Genomics boom puts strain on data storage, electricity grid. Story

> Alibaba, BGI and Intel team up for precision medicine project. Article

> Chinese sequencing sector heats up as BGI, Direct Genomics prepare products. Item

> FDA seeks industry feedback on virtual and BYOD clinical trials. More

Pharma Marketing News

> Shire dodges HAE competition with $5.9B Dyax buyout. Item

> Sanofi's Auvi-Q recall puts Mylan's rival EpiPen in full control of blockbuster market. Report

> Novartis sees doc-education push, DTC as crucial to amping up Entresto launch. Story

> Feds arrest, charge ex-Warner Chilcott sales execs in kickbacks case. More

> GSK readies respiratory sales force to challenge Xolair in severe asthma. Article

Suggested Articles

Comet Therapeutics unveiled itself with $28.5 million in series A financing and biopharma veteran David De Graaf at the helm.

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.